Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Beijing Puyi Biotechnology

Request full access

High-throughput, long-read nanopore gene sequencing systems.

Haidian, ChinaFounded 2021Biotech & Life Sciences

About Beijing Puyi Biotechnology

Beijing Puyi Biotechnology Co., Ltd. (Polyseq) is a life sciences company focused on the development and commercialization of nanopore-based gene sequencing systems. The company leverages proprietary technology to produce high-accuracy, high-throughput, long-read, and low-cost nanopore sequencers, along with the necessary reagents and consumables. The firm's product portfolio is built upon a proprietary sequencing chemistry system, which is based on independently resolved atomic-scale structures of novel biological nanopores and integrated with nucleic acid chemistry and protein engineering. This is combined with integrated circuit chips, software engineering, and deep learning algorithms to create a high-performance sequencing platform.

Polyseq offers a range of products including various nanopore sequencers like the PolyseqOne, PolyseqHive, and PolyseqX2, which offer different throughput capabilities. For example, the PolyseqX2 is designed for high-throughput applications with a capacity of up to 800 GB and can achieve megabase-level ultra-long read lengths. The company also provides sequencing chips, such as the PolyseqCell and PolyseqXCell, and a variety of test kits for library preparation. A key feature of their technology is the reusable and cleanable chip design, which aims to significantly reduce sequencing costs. Their C2.0 Sequencing Chemistry System is designed to provide consistent 99% accuracy across various applications by using a novel nanopore protein and speed-control protein.

The company's technology has a wide array of applications across multiple sectors. These include research sequencing, pathogen detection, genetic disease testing, tumor detection, forensic identification, reproductive health, pharmaceutical quality control, public health and epidemic prevention, and customs inspection. For instance, in pathogen detection, the technology allows for rapid and accurate identification to guide clinical treatment. In March 2026, the company announced it had raised CNY 150 million in a funding round that included investors such as IDG Capital and CAS Venture Capital Management.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
1
Dealroom signal
22.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Genetics and genomics, Health Diagnostics, Biotech and Pharma, Techbio, medical testing, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Mar 2026 $21M $83M Wondfo Biotech · BOC Capital · Changfa · IDG Capital ↗
SERIES A✓Equity / VC May 2023 $14M $55M IDG Capital · Wondfo Biotech · ISeed Capital · Sanmei Investment ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Beijing Puyi Biotechnology website traffic

Latest recorded traffic for Beijing Puyi Biotechnology is 220 monthly website visits, down 46.3% over the last three months.

Latest monthly visits220 3-month web change-46.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Beijing Puyi Biotechnology in the Haidian ecosystem

Live from Dealroom

The Beijing Puyi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Wondfo Biotech
  • Sanmei Investment
  • IDG Capital
  • ISeed Capital
  • Shuimu Venture Capital
  • BOC Capital
  • Changfa
  • Guoke Venture Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Haidian HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Beijing Puyi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Beijing Puyi Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.